Protalix BioTherapeutics (PLX) EBT (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly EBT of $21.1 million for Q1 2026, up 666.48% year-over-year from $2.8 million in Q1 2025, and up 664.21% quarter-over-quarter from -$3.7 million in Q4 2025.
Protalix BioTherapeutics (PLX) EBT (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' EBT history runs 17 years deep, the most recent figure standing at $21.1 million for Q1 2026.
- In Q1 2026, EBT rose 666.48% year-over-year to $21.1 million; the TTM figure through Mar 2026 stood at $20.3 million (up 109.15% YoY), while the FY2025 annual figure was -$4.6 million, down 152.62% from the prior year.
- EBT for Q1 2026 stood at $21.1 million, up from -$3.7 million in the prior quarter.
- The five-year high for EBT was $21.1 million in Q1 2026, with the low at -$22.1 million in Q4 2023.
- The 5-year median for EBT is -$2.3 million (2022), against an average of $223882.4.
- The sharpest annual moves came in 2023 and 2026: EBT slumped 587.01% in 2023, then jumped 666.48% in 2026.
- Protalix BioTherapeutics' EBT stood at -$3.2 million in 2022, then plunged by 587.01% to -$22.1 million in 2023, then jumped by 153.8% to $11.9 million in 2024, then plunged by 131.58% to -$3.7 million in 2025, then soared by 664.21% to $21.1 million in 2026.
- Business Quant data shows PLX's EBT at $21.1 million in Q1 2026, -$3.7 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 4.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.86 Mn |
| Mar 31, 2026 | 21.14 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Sep 30, 2025 | 2.24 Mn |
| Jun 30, 2025 | 661,000.00 |
| Mar 31, 2025 | -3.73 Mn |
| Dec 31, 2024 | 11.86 Mn |
| Sep 30, 2024 | 3.84 Mn |
| Jun 30, 2024 | -2.27 Mn |
| Mar 31, 2024 | -4.73 Mn |
| Dec 31, 2023 | -22.05 Mn |
| Sep 30, 2023 | -1.72 Mn |
| Jun 30, 2023 | 19.65 Mn |
| Mar 31, 2023 | -2.94 Mn |
| Dec 31, 2022 | -3.21 Mn |
| Sep 30, 2022 | -3.57 Mn |
| Jun 30, 2022 | -5.33 Mn |
| Mar 31, 2022 | -2.29 Mn |
| Dec 31, 2021 | -6.61 Mn |
| Sep 30, 2021 | -4.30 Mn |